Corestemchemon
코아스템켐온 · 166480
Health Care Pharmaceuticals · KOSDAQ
Market cap US$116.1M (₩160.2B)
Overview
Corestemchemon develops and supplies stem-cell therapies, medicines that use living cells to treat rare and hard-to-cure diseases, to patients in South Korea, and also runs a contract research division that conducts pre-clinical (animal-based) safety and efficacy testing on behalf of drug developers.
It is listed on KOSDAQ, South Korea's tech and small-cap exchange. The business operates two distinct divisions: a biopharmaceuticals arm that manufactures and supplies approved stem-cell treatments, and a non-clinical contract research arm that provides testing services to outside clients.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$24.4M
- FY2024US$20.8M
- FY2025US$14.6M
Operating profit
- FY2023−US$14.3M
- FY2024−US$16M
- FY2025−US$15.4M
Net income
- FY2023−US$12.8M
- FY2024−US$19M
- FY2025−US$19.4M
Key ratios (FY2025)
Why it matters
The company absorbed its subsidiary Chemon, one of South Korea's leading non-clinical contract research organisations, through a merger, creating its current two-division structure.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?